1-3 of 3
M.L. den Boer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dasatinib (SPRYCEL®) in Children and Adolescents with Relapsed or Refractory Leukemia: Preliminary Results of the CA180018 Phase I/II Study from the ITCC Consortium.

Christian M. Zwaan, MD, M.L. den Boer, MD, H.B. Beverloo, V.H.J. van der Velden, J.M.A. Van Tornout, MD, D. Derreumaux, A. Baruchel, C. Rizzari, P. Kearns, R. Pieters
Journal: Blood
Blood (2007) 110 (11): 1049.
https://doi.org/10.1182/blood.V110.11.1049.1049
Published: 2007
Journal Articles

Dasatinib (SPRYCEL®) in Children and Adolescents with Relapsed or Refractory Leukemia: Preliminary Results of the CA180018 Phase I/II Study.

Christian M. Zwaan, M.L. den Boer, B. Beverloo, V. van der Velden, A. Countouriotis, L. Strauss, L. Astier, A. Apanovitch, J. Landman-Parker, P. Kearns
Journal: Blood
Blood (2006) 108 (11): 2162.
https://doi.org/10.1182/blood.V108.11.2162.2162
Published: 2006
Journal Articles

Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia

M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, G.J.L. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, A.J.P. Veerman
Journal: Blood
Blood (1998) 91 (6): 2092–2098.
https://doi.org/10.1182/blood.V91.6.2092
Published: 1998